News

Redefining Treatment Timelines for Platinum-Resistant Ovarian Cancer

“Integrating clinical trials and newer therapies earlier in a patient’s ovarian cancer treatment journey can make a significant difference in their outcome,” said Angela Jain, MD, Associate Professor, Department of Hematology/Oncology; ...

News

From Fellowship to Faculty: Building a Fox Chase Career

Arielle Weiss, MD, Assistant Professor, Department of Surgery, and Jason Conger, MD, Assistant Professor, Department of Surgery, both in the Division of Gynecologic Oncology, came to Fox Chase Cancer Center shaped by different experiences, ...

News

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression ...

News

GYNECOLOGIC CANCER PROGRAM

Comprehensive Care That Empowers Patients Through Risk Assessment, Prevention, Detection, Treatment, and Survivorship

News

For Recurrent Gyn Cancer, Immunotherapy is Becoming a Powerful Treatment Option

Gynecologic cancers that recur are typically treated as chronic diseases. Increasingly, oncologists at Fox Chase Cancer Center are turning to immunotherapy as a powerful option for chronic endometrial, cervical, and ovarian cancer management.

Video

Life-Saving Advice About Postmenopausal Bleeding

In postmenopausal patients, uterine bleeding may mean cancer.